Methylated PIH1D1 as a Heart-Specific Biomarker for Anthracycline-Induced Cardiac Remodeling in Breast Cancer Patients.

Fiche publication

Date publication

mars 2026

Journal

JACC. Basic to translational science

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DESAUBRY Laurent , Dr NEBIGIL-DESAUBRY Canan

Tous les auteurs :
Hsu PY, Huang WH, Lee YY, Passier R, Li SC, Hong CL, Hung SK, Lin HY, Lin CH, Chien CY, Li YD, Lee HC, Désaubry L, Nebigil CG, Chan MWY

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41819055

Résumé

Anthracyclines, key chemotherapy agents, pose cardiotoxicity risks. In a 3-year study of 89 breast cancer patients treated with doxorubicin or epirubicin, more than 50% showed reduced left ventricular ejection fraction and progressive ventricular dilation. Although troponin-I flagged acute damage, it failed to predict long-term remodeling. Using a human methylome atlas, researchers identified 33 heart-specific methylated CpG sites and validated methylated PIH1D1 (mPIH1D1) as a novel biomarker. Elevated mPIH1D1 levels strongly correlated with ventricular dilation but not left ventricular ejection fraction decline, indicating its sensitivity to early cardiac remodeling. mPIH1D1 may complement troponin-I in risk assessment and cardiotoxicity management for patients undergoing anthracycline-based chemotherapy.